Literature DB >> 18456736

Chronic treatment with insulin-like growth factor I enhances myocyte contraction by upregulation of Akt-SERCA2a signaling pathway.

Song-Jung Kim1, Maha Abdellatif, Sharat Koul, George J Crystal.   

Abstract

Chronic treatment with insulin-like growth factor I (IGF-I) improves contractile function in congestive heart failure and ischemic cardiomyopathy. The present study investigated the effect of chronic treatment with IGF-I on intrinsic myocyte function and the role of the phosphatidylinositol (PI)3-kinase-Akt-sarco(endo)plasmic reticulum Ca(2+)-ATPase (SERCA)2a signaling cascade in these responses. Myocytes were isolated from 23 adult rats and cultured with and without IGF-I (10(-6) M). After 48 h of treatment, myocyte function was evaluated. IGF-I increased contractile function (percent contraction, 7.7 +/- 0.3% vs. 4.5 +/- 0.3%; P < 0.01) and accelerated relaxation time (time for 70% relengthening, 81 +/- 4 vs. 106 +/- 5 ms; P < 0.05) compared with untreated myocytes [control (Con)]. The enhanced function was associated with an increase in Ca(2+) transients assessed by fura-2 (340/380 nm; IGF-I, 0.42 +/- 0.02 vs. Con, 0.25 +/- 0.01; P < 0.01). The PI3-kinase inhibitor LY-249002 (10(-9) M) abolished the enhanced function caused by IGF-I. IGF-I increased both Akt and SERCA2a protein levels 2.5- and 4.8-fold, respectively, compared with those of Con (P < 0.01); neither phospholamban nor calsequestrin was affected. To evaluate whether the SERCA2a protein was directly mediated by Akt-SERCA2a signaling, IGF-I-induced changes in the SERCA2a protein were compared in myocytes transfected with adenovirus harboring either constitutively active Akt [multiplicity of infection (MOI), 15] or dominant negative Akt (dnAkt; MOI, 15). The ability of IGF-I to upregulate the SERCA2a protein in myocytes transfected with active Akt was absent in dnAkt myocytes. Taken together, our findings indicate that chronic treatment with IGF-I enhances intrinsic myocyte function and that this effect is due to an enhancement in intracellular Ca(2+) handling, secondary to the activation of the PI3-kinase-Akt-SERCA2a signaling cascade.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18456736      PMCID: PMC2494754          DOI: 10.1152/ajpheart.00298.2008

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  38 in total

1.  Altered excitation-contraction coupling in myocytes from remodeled myocardium after chronic myocardial infarction.

Authors:  Young-Kwon Kim; Song-Jung Kim; Christopher M Kramer; Atsuko Yatani; Gen Takagi; Sunil Mankad; Gyula P Szigeti; Deepak Singh; Sanford P Bishop; Richard P Shannon; Dorothy E Vatner; Stephen F Vatner
Journal:  J Mol Cell Cardiol       Date:  2002-01       Impact factor: 5.000

2.  Positive inotropic effect of insulin-like growth factor-1 on normal and failing cardiac myocytes.

Authors:  S Kinugawa; H Tsutsui; T Ide; R Nakamura; K Arimura; K Egashira; A Takeshita
Journal:  Cardiovasc Res       Date:  1999-07       Impact factor: 10.787

3.  Phosphorylation of phospholamban by calcium-activated, phospholipid-dependent protein kinase. Stimulation of cardiac sarcoplasmic reticulum calcium uptake.

Authors:  M A Movsesian; M Nishikawa; R S Adelstein
Journal:  J Biol Chem       Date:  1984-07-10       Impact factor: 5.157

4.  A novel mechanism for myocardial stunning involving impaired Ca(2+) handling.

Authors:  S J Kim; R K Kudej; A Yatani; Y K Kim; G Takagi; R Honda; D A Colantonio; J E Van Eyk; D E Vatner; R L Rasmusson; S F Vatner
Journal:  Circ Res       Date:  2001-10-26       Impact factor: 17.367

5.  Treatment with dimethylthiourea prevents left ventricular remodeling and failure after experimental myocardial infarction in mice: role of oxidative stress.

Authors:  S Kinugawa; H Tsutsui; S Hayashidani; T Ide; N Suematsu; S Satoh; H Utsumi; A Takeshita
Journal:  Circ Res       Date:  2000-09-01       Impact factor: 17.367

6.  Glycogen synthase kinase 3beta regulates GATA4 in cardiac myocytes.

Authors:  C Morisco; K Seta; S E Hardt; Y Lee; S F Vatner; J Sadoshima
Journal:  J Biol Chem       Date:  2001-05-29       Impact factor: 5.157

7.  Impaired cardiac excitation-contraction coupling in ventricular myocytes from Ames dwarf mice with IGF-I deficiency.

Authors:  Jun Ren; Holly M Brown-Borg
Journal:  Growth Horm IGF Res       Date:  2002-04       Impact factor: 2.372

8.  Insulin-like growth factor-1 exerts Ca2+-dependent positive inotropic effects in failing human myocardium.

Authors:  Dirk von Lewinski; Kerstin Voss; Swen Hülsmann; Harald Kögler; Burkert Pieske
Journal:  Circ Res       Date:  2003-02-07       Impact factor: 17.367

9.  Mechanism of enhanced cardiac function in mice with hypertrophy induced by overexpressed Akt.

Authors:  Young-Kwon Kim; Song-Jung Kim; Atsuko Yatani; Yanhong Huang; Germana Castelli; Dorothy E Vatner; Jing Liu; Qizhi Zhang; Gissela Diaz; Renata Zieba; Jill Thaisz; Alessandra Drusco; Carlo Croce; Junichi Sadoshima; Gianluigi Condorelli; Stephen F Vatner
Journal:  J Biol Chem       Date:  2003-09-16       Impact factor: 5.157

10.  A preliminary study of growth hormone in the treatment of dilated cardiomyopathy.

Authors:  S Fazio; D Sabatini; B Capaldo; C Vigorito; A Giordano; R Guida; F Pardo; B Biondi; L Saccà
Journal:  N Engl J Med       Date:  1996-03-28       Impact factor: 91.245

View more
  19 in total

1.  How to make rapid eye movements "rapid": the role of growth factors for muscle contractile properties.

Authors:  Tian Li; Cheng-Yuan Feng; Christopher S von Bartheld
Journal:  Pflugers Arch       Date:  2011-01-29       Impact factor: 3.657

2.  Improved function of the failing rat heart by regulated expression of insulin-like growth factor I via intramuscular gene transfer.

Authors:  N Chin Lai; Tong Tang; Mei Hua Gao; Miho Saito; Atsushi Miyanohara; H Kirk Hammond
Journal:  Hum Gene Ther       Date:  2012-01-12       Impact factor: 5.695

Review 3.  AKT signalling in the failing heart.

Authors:  Antoine H Chaanine; Roger J Hajjar
Journal:  Eur J Heart Fail       Date:  2011-06-30       Impact factor: 15.534

4.  It's all in the timing: modeling isovolumic contraction through development and disease with a dynamic dual electromechanical bioreactor system.

Authors:  Kathy Ye Morgan; Lauren Deems Black
Journal:  Organogenesis       Date:  2014-10-31       Impact factor: 2.500

Review 5.  SERCA control of cell death and survival.

Authors:  Elie R Chemaly; Luca Troncone; Djamel Lebeche
Journal:  Cell Calcium       Date:  2017-07-12       Impact factor: 6.817

6.  Mimicking isovolumic contraction with combined electromechanical stimulation improves the development of engineered cardiac constructs.

Authors:  Kathy Ye Morgan; Lauren Deems Black
Journal:  Tissue Eng Part A       Date:  2014-04-07       Impact factor: 3.845

7.  Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice.

Authors:  Isotta Chimenti; Rachel Ruckdeschel Smith; Tao-Sheng Li; Gary Gerstenblith; Elisa Messina; Alessandro Giacomello; Eduardo Marbán
Journal:  Circ Res       Date:  2010-01-28       Impact factor: 17.367

8.  Excitation-contraction coupling in ventricular myocytes is enhanced by paracrine signaling from mesenchymal stem cells.

Authors:  J DeSantiago; D J Bare; I Semenov; R D Minshall; D L Geenen; B M Wolska; K Banach
Journal:  J Mol Cell Cardiol       Date:  2012-03-23       Impact factor: 5.000

9.  Short-term akt activation in cardiac muscle cells improves contractile function in failing hearts.

Authors:  Ichiro Shiojima; Stephan Schiekofer; Jochen G Schneider; Kurt Belisle; Kaori Sato; Martin Andrassy; Gennaro Galasso; Kenneth Walsh
Journal:  Am J Pathol       Date:  2012-09-30       Impact factor: 4.307

10.  CYP2J2-derived epoxyeicosatrienoic acids suppress endoplasmic reticulum stress in heart failure.

Authors:  Xingxu Wang; Li Ni; Lei Yang; Quanlu Duan; Chen Chen; Matthew L Edin; Darryl C Zeldin; Dao Wen Wang
Journal:  Mol Pharmacol       Date:  2013-10-21       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.